Analytical Data
-
Gene name
RANk
- Application
-
Alternative Names
RANk；RANK；Tumor necrosis factor receptor superfamily member 11A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y6Q6
-
Expression Region
29-313aa
-
AA Sequence
QIAPPCTSEKHYEHLGRCCNKCEPGKYMSSKCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGYHWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLPGLIILLLFASVALVAAIIFGVCYRKKGKALTANLWHWINEACGRLSGDKESSGDSCVSTHTANFGQQGACEGVLLLTLEEKTFPEDMCYPDQGGVCQGTCV
-
Molecular Weight
55 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RANK, or Receptor Activator of Nuclear Factor kappa-B, is a crucial protein in the immune system, primarily involved in the regulation of osteoclastogenesis, which is the process that leads to bone resorption. The activation of RANK by its ligand, RANKL, triggers various signaling pathways that impact not only bone metabolism but also immune responses, cellular survival, and inflammation. Dysregulation of RANK and RANKL signaling has been linked to several pathologies, including osteoporosis, rheumatoid arthritis, and various cancers, making it a significant target for therapeutic interventions. Research into RANK and its related proteins has gained momentum due to their potential role in modulating bone density and inflammatory diseases. Scientists are particularly interested in developing RANK inhibitors or neutralizing antibodies to mitigate the adverse effects of excessive RANKL signaling. Additionally, understanding the structural biology of RANK can provide insights into its interactions and mechanisms, paving the way for novel treatment approaches. As such, RANK has emerged as a prominent focus in both basic and clinical research, with ongoing studies aimed at elucidating its role and potential as a drug target in various diseases associated with bone and immune system dysregulation.
